MedicineBiology

An immune-active tumor microenvironment favors clinical response to ipilimumab

Rui-Ru Ji, S. Chasalow, Lisu Wang, O. Hamid, H. Schmidt, J. Cogswell, S. Alaparthy, D. Berman, M. Jure-Kunkel, N. Siemers, J. Jackson, V. Shahabi

2012.7.1CANCER IMMUNOLOGY IMMUNOTHERAPY

DOI: 10.1007/s00262-011-1172-6

tlooto Summary

These results support the proposed mechanism of action of ipilimumab, suggesting that cell-mediated immune responses play an important role in the antitumor activity of ipILimumab.

Abstract

Abstract is not available.

Citation format

JI, Rui-Ru, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61: 1019–1031.